http://www.cnr.it/ontology/cnr/individuo/prodotto/ID4608

Are gadolinium contrast agents suitable for gadolinium neutron capture therapy? (Articolo in rivista)

Type

Prodotto della ricerca (Classe)
Articolo in rivista (Classe)

Label

Are gadolinium contrast agents suitable for gadolinium neutron capture therapy? (Articolo in rivista) (literal)

Anno

2005-01-01T00:00:00+01:00 (literal)

Alternative label

De Stasio G.1; Rajesh D.2; Casalbore P.3; Daniels M.J.4; Erhardt R.J.5; Frazer B.H.6; Wiese L.M.7; Richter K.L.8; Sonderegger B.R..9; Gilbert B.10; Schaub S.11; Cannara 12; et al. (2005)
Are gadolinium contrast agents suitable for gadolinium neutron capture therapy?
in Neurological research (N. Y.)
(literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

De Stasio G.1; Rajesh D.2; Casalbore P.3; Daniels M.J.4; Erhardt R.J.5; Frazer B.H.6; Wiese L.M.7; Richter K.L.8; Sonderegger B.R..9; Gilbert B.10; Schaub S.11; Cannara 12; et al. (literal)

Pagina inizio

387 (literal)

Pagina fine

398 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#altreInformazioni

Impact Factor = 1.216 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

27(4) (literal)

Rivista

Neurological research (Rivista)

Note

ISI Web of Science (WOS) (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

1,4,5,6,7,9,10,12 = University of Wisconsin-Madison, Department of Physics and Synchrotron Radiation Center, 3731 Schneider Drive, Stoughton WI 53589, USA; 2 = University of Wisconsin, Department of Human Oncology, Madison WI 53792, USA; 3 = Istituto di Biologia Cellulare, CNR, Viale Marx 15, I-00137 Roma, Italy; 8 = Bob Jones University, Greenville, SC 29614, USA; 11 = Biomedical Engineering Laboratory, PSE-A, Swiss Federal Institute of Technology, CH-1015 Lausanne, Switzerland; 13 = Hengelweg 37, CH-5303 Würenlingen, Switzerland; 14,15 = Lawrence Berkeley National Laboratory, 1 Cyclotron Rd. MS 6-2100, Berkeley, CA 94720, USA; 17 = Istituto di Anatomia Patologica, Universita' Cattolica del Sacro Cuore, Largo A. Gemelli 8, I-00168 Roma, Italy; 19 = Istituto di Neurobiologia e Medicina Molecolare, CNR, Viale Marx 15, 00137 Roma, Italy; 21 = Istituto di Neurochirurgia, Universita' Cattolica del Sacro Cuore, Largo A. Gemelli 8, I-00168 Roma, Italy. (literal)

Titolo

Are gadolinium contrast agents suitable for gadolinium neutron capture therapy? (literal)

Abstract

OBJECTIVE: Gadolinium neutron capture therapy (GdNCT) is a potential treatment for malignant tumors based on two steps: (1) injection of a tumor-specific (157)Gd compound; (2) tumor irradiation with thermal neutrons. The GdNC reaction can induce cell death provided that Gd is proximate to DNA. Here, we studied the nuclear uptake of Gd by glioblastoma (GBM) tumor cells after treatment with two Gd compounds commonly used for magnetic resonance imaging, to evaluate their potential as GdNCT agents. METHODS: Using synchrotron X-ray spectromicroscopy, we analyzed the Gd distribution at the subcellular level in: (1) human cultured GBM cells exposed to Gd-DTPA or Gd-DOTA for 0-72 hours; (2) intracerebrally implanted C6 glioma tumors in rats injected with one or two doses of Gd-DOTA, and (3) tumor samples from GBM patients injected with Gd-DTPA. RESULTS: In cell cultures, Gd-DTPA and Gd-DOTA were found in 84% and 56% of the cell nuclei, respectively. In rat tumors, Gd penetrated the nuclei of 47% and 85% of the tumor cells, after single and double injection of Gd-DOTA, respectively. In contrast, in human GBM tumors 6.1% of the cell nuclei contained Gd-DTPA. DISCUSSION: Efficacy of Gd-DTPA and Gd-DOTA as GdNCT agents is predicted to be low, due to the insufficient number of tumor cell nuclei incorporating Gd. Although multiple administration schedules in vivo might induce Gd penetration into more tumor cell nuclei, a search for new Gd compounds with higher nuclear affinity is warranted before planning GdNCT in animal models or clinical trials. (literal)

Prodotto di